Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 80

Sort by

Sort Order Select

Journal Articles

Frontline tyrosine kinase inhibitor selection influences eventual treatment-free remission eligibility and sustained treatment-free remission: A registry analysis of patients treated at CML referral sites in Australia

Naranie Shanmuganathan, Susan Branford, David Yeung, David Ross, Timothy Hughes

Blood (2025) 146 (Supplement 1): 2008.

https://doi.org/10.1182/blood-2025-2008

Published: 2025

Journal Articles

Numerous clinically-detected asciminib-resistant BCR::ABL1 mutations disrupt allostery and confer cross-resistance to the novel clinically-active allosteric TKI tgrx-678

Ariel Leyte-Vidal, Ian Outhwaite, Kaeli Miller, Emma Gebauer, Ailin Alvarez, Carlyn Leavitt, Nellie Ahmadieh, Brian Farrell, Isabelle Kwan, Susan Branford, Muneeza Maqsood, David Yeung, Timothy Hughes, Vivian Oehler, Delphine Rea, Ralf Landgraf, Ivette Bahar, Markus Seeliger, Neil Shah

Blood (2025) 146 (Supplement 1): 1516.

https://doi.org/10.1182/blood-2025-1516

Published: 2025

Journal Articles

Durable efficacy of lenzilumab plus azacitidine in newly diagnosed proliferative CMML patients: Interim analysis after four years of study commencement

Devendra Hiwase, David Ross, David Yeung, Agnes Yong, Steven Lane, Anna Brown, Chun Yew Fong, Timothy Hughes, John Reynolds, Daniel Thomas

Blood (2025) 146 (Supplement 1): 3855.

https://doi.org/10.1182/blood-2025-3855

Published: 2025

Journal Articles

High dose ascorbate downregulates innate immune cytokines in the bone marrow of TET2 mutant chronic myelomonocytic leukemia

Maha Kamel, Monika Kutyna, Nirmal Robinson, David Ross, David Yeung, Agnes Yong, Anna Brown, Timothy Hughes, Devendra Hiwase, Daniel Thomas

Blood (2025) 146 (Supplement 1): 2065.

https://doi.org/10.1182/blood-2025-2065

Published: 2025

Journal Articles

Unravelling the epigenetic drivers of chip – MDS/CMML – AML progression through novel methylation-sensitive regulatory elements

Yanjing Liu, Li Chai, Devendra Hiwase, David Ross, David Yeung, Agnes Yong, Steven Lane, Anna Brown, Chun Yew Fong, Timothy Hughes, John Reynolds, Daniel Thomas, Daniel Tenen, Mahmoud Bassal

Blood (2025) 146 (Supplement 1): 3231.

https://doi.org/10.1182/blood-2025-3231

Published: 2025

Journal Articles

Somatic mutations at diagnosis in patients with chronic Phase CML receiving frontline imatinib are associated with a higher rate of treatment failure: First analysis from the international CML foundation (iCMLf) genomics alliance on the harmony platform

Blood (2025) 146 (Supplement 1): 75.

https://doi.org/10.1182/blood-2025-75

Published: 2025

Journal Articles

A single-cell atlas of diagnostic bone marrow to uncover the origins of CML relapse following therapy cessation

Vaidehi Krishnan, Xi Ren, Kian Leong Lee, Radhika Sonthalia, Prasanna Venkatesh, Mengge Yu, Pavithra Shyamsunder, John Ouyang, Xinyi Yang, Florian Schmidt, Verity Saunders, Naranie Shanmuganathan, Charles Chuah, Naoto Takahashi, Susan Branford, Timothy Hughes, Shyam Prabhakar, Sin Tiong Ong

Blood (2025) 146 (Supplement 1): 74.

https://doi.org/10.1182/blood-2025-74

Published: 2025

Journal Articles

Distinct patterns of mutant ASXL1 over time and their implications for treatment failure (TF) and BCR::ABL1 mutation development in newly diagnosed patients with chronic myeloid leukemia in chronic phase (CML-CP) treated with asciminib (ASC) vs investigator-selected tyrosine kinase inhibitors (IS-TKI) in the ASC4FIRST study

Blood (2025) 146 (Supplement 1): 73.

https://doi.org/10.1182/blood-2025-73

Published: 2025

Journal Articles

Asciminib (ASC) demonstrates continued improvement in patient-reported outcomes (PROs) vs investigator-selected tyrosine kinase inhibitors (IS-TKIs) in newly diagnosed chronic myeloid leukemia (CML): ASC4FIRST week 96 analysis

Blood (2025) 146 (Supplement 1): 1997.

https://doi.org/10.1182/blood-2025-1997

Published: 2025

Journal Articles

Whole genome sequencing reveals that the Philadelphia chromosome (Ph) can evolve and gain complex chromoplectic sequence rearrangements associated with tyrosine kinase inhibitor (TKI) resistance

Susan Branford, Carol Wadham, Nur Hezrin Shahrin, Verity Saunders, Rosalie Kenyon, Ming Lin, Dominic Kaczorowski, Muneeza Maqsood, Hamish Scott, John Toubia, Naranie Shanmuganathan, Chung Kok, Timothy Hughes

Blood (2025) 146 (Supplement 1): 3770.

https://doi.org/10.1182/blood-2025-3770

Published: 2025

Journal Articles

CARDINAL: A Phase 1 study of TERN-701, a novel investigational allosteric BCR::ABL1 inhibitor for patients with previously treated CML

Elias Jabbour, Timothy Hughes, Richard Van Etten, David Andorsky, Gonzalo Carreño, Philipp le Coutre, Omer Jamy, Pilar Giraldo, Dong-Wook Kim, Vivian Oehler, Andreas Hochhaus, Jorge Cortes, Michael Mauro, Tonya Marmon, Leanne Holes, Emil Kuriakose, Hagop Kantarjian, Delphine Rea

Blood (2025) 146 (Supplement 1): 901.

https://doi.org/10.1182/blood-2025-901

Published: 2025

Journal Articles

High rates of deep molecular response (DMR) in patients (pts) with chronic myeloid leukemia in chronic Phase (CML-CP) who have not achieved dmr after ≥1 year of prior imatinib (IMA) in the asciminib (ASC) monotherapy arm of the Phase 2 ASC4MORE study

Jorge Cortes, Giuseppe Saglio, Jan Geissler, Jiri Mayer, Gabriel Etienne, Michael Fillitz, Elvira Mora Casterá, Shruti Kapoor, Ana Paula Cardoso, Ugo Okoroji, Amila Sarac, Matthias Hoch, Sara Quenet, Timothy Hughes

Blood (2025) 146 (Supplement 1): 5552.

https://doi.org/10.1182/blood-2025-5552

Published: 2025

Journal Articles

Improved long-term tolerability with asciminib (ASC) vs investigator-selected (IS) tyrosine kinase inhibitors (TKIs) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Week 96 exploratory analysis of the phase 3 ASC4FIRST trial

Blood (2025) 146 (Supplement 1): 5549.

https://doi.org/10.1182/blood-2025-5549

Published: 2025

Journal Articles

A Risk Model for CML Patients with COVID-19: Importance of Molecular Response in the Context of Age, Comorbidities and Country Income

Jerald P. Radich, Chung Hoow Kok, Ekaterina Yu. Chelysheva, Jorge E. Cortes, Qian Jiang, Michael Mauro, Dragana Milojkovic, Beatriz Moiraghi, Franck E. Nicolini, Matilda Ongondi, Katia B Pagnano, Daniela Žácková, Delphine Rea, Nicola Evans, Timothy Hughes

Blood (2022) 140 (Supplement 1): 9617–9619.

https://doi.org/10.1182/blood-2022-165855

Published: 2022

Journal Articles

Additional Mutational Events at Diagnosis of CML Confer Inferior Failure-Free Survival and Molecular Response for Patients Treated with Frontline Imatinib but Not for Patients Treated with Frontline Second-Generation Tyrosine Kinase Inhibitors

Naranie Shanmuganathan, David T Yeung, Carol Wadham, Nur Hezrin Shahrin, Adelina Fernandes, Jinghua Feng, Verity A Saunders, Ming Lin, Rosalie Kenyon, Rob King, Paul Wang, David M Ross, Andreas W Schreiber, Timothy Hughes, Susan Branford

Blood (2022) 140 (Supplement 1): 805–806.

https://doi.org/10.1182/blood-2022-158743

Published: 2022

Journal Articles

First-in-Human Study of Elvn-001, a Highly Selective BCR::ABL1 Tyrosine Kinase Inhibitor, in Patients with Chronic Myeloid Leukemia Who Failed Previous Tyrosine Kinase Inhibitor Therapies

Timothy Hughes, Michael Mauro, Susan Branford, Wei Deng, Qi Wang, Helen Collins, Andreas Hochhaus

Blood (2022) 140 (Supplement 1): 6780–6781.

https://doi.org/10.1182/blood-2022-170401

Published: 2022

Journal Articles

Senolytic Therapy Can Reverse Senescent Bone Marrow Stroma of Therapy-Related Myeloid Neoplasm

Monika M Kutyna, Chung Hoow Kok, Yoon Lim, David Campbell, Sharon Paton, Chloe AL Thompson-Peach, Kelly SY Lim, Timothy Hughes, Sharad Kumar, Daniel Thomas, Stan Gronthos, Devendra Hiwase

Blood (2022) 140 (Supplement 1): 9755–9756.

https://doi.org/10.1182/blood-2022-167994

Published: 2022

Journal Articles

Clinical Outcomes of Chronic Myeloid Leukaemia (CML) Patients on Asciminib through the Managed Access Program (MAP) in Australia

Lynette C.Y. Chee, Nora Lee, Andrew Grigg, Melissa Chen, Anthony Schwarer, Jeff Szer, David T Yeung, Timothy Hughes, Naranie Shanmuganathan

Blood (2022) 140 (Supplement 1): 6800–6802.

https://doi.org/10.1182/blood-2022-163221

Published: 2022

Journal Articles

ASC4FIRST: A Phase III Study of Asciminib vs Investigator-Selected Tyrosine Kinase Inhibitor in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Timothy Hughes, Jorge E. Cortes, Naoto Takahashi, Richard A. Larson, Ghayas C. Issa, Felice Bombaci, Nicholas Ramscar, Shruti Kapoor, Sophie Ifrah, Andreas Hochhaus

Blood (2022) 140 (Supplement 1): 6767–6768.

https://doi.org/10.1182/blood-2022-162249

Published: 2022

Journal Articles

Molecular Response of ≤10% BCR::ABL1 IS Is Predictive of Positive Outcomes in Treatment-Resistant Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Ponatinib from the Phase 2 Optic Trial

Blood (2022) 140 (Supplement 1): 6760–6762.

https://doi.org/10.1182/blood-2022-157956

Published: 2022

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Frontline tyrosine kinase inhibitor selection influences eventual treatment-free remission eligibility and sustained treatment-free remission: A registry analysis of patients treated at CML referral sites in Australia

Numerous clinically-detected asciminib-resistant BCR::ABL1 mutations disrupt allostery and confer cross-resistance to the novel clinically-active allosteric TKI tgrx-678

Durable efficacy of lenzilumab plus azacitidine in newly diagnosed proliferative CMML patients: Interim analysis after four years of study commencement

High dose ascorbate downregulates innate immune cytokines in the bone marrow of TET2 mutant chronic myelomonocytic leukemia

Unravelling the epigenetic drivers of chip – MDS/CMML – AML progression through novel methylation-sensitive regulatory elements

Somatic mutations at diagnosis in patients with chronic Phase CML receiving frontline imatinib are associated with a higher rate of treatment failure: First analysis from the international CML foundation (iCMLf) genomics alliance on the harmony platform

A single-cell atlas of diagnostic bone marrow to uncover the origins of CML relapse following therapy cessation

Asciminib (ASC) demonstrates continued improvement in patient-reported outcomes (PROs) vs investigator-selected tyrosine kinase inhibitors (IS-TKIs) in newly diagnosed chronic myeloid leukemia (CML): ASC4FIRST week 96 analysis

Whole genome sequencing reveals that the Philadelphia chromosome (Ph) can evolve and gain complex chromoplectic sequence rearrangements associated with tyrosine kinase inhibitor (TKI) resistance

CARDINAL: A Phase 1 study of TERN-701, a novel investigational allosteric BCR::ABL1 inhibitor for patients with previously treated CML

High rates of deep molecular response (DMR) in patients (pts) with chronic myeloid leukemia in chronic Phase (CML-CP) who have not achieved dmr after ≥1 year of prior imatinib (IMA) in the asciminib (ASC) monotherapy arm of the Phase 2 ASC4MORE study

Improved long-term tolerability with asciminib (ASC) vs investigator-selected (IS) tyrosine kinase inhibitors (TKIs) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Week 96 exploratory analysis of the phase 3 ASC4FIRST trial

A Risk Model for CML Patients with COVID-19: Importance of Molecular Response in the Context of Age, Comorbidities and Country Income

Additional Mutational Events at Diagnosis of CML Confer Inferior Failure-Free Survival and Molecular Response for Patients Treated with Frontline Imatinib but Not for Patients Treated with Frontline Second-Generation Tyrosine Kinase Inhibitors

First-in-Human Study of Elvn-001, a Highly Selective BCR::ABL1 Tyrosine Kinase Inhibitor, in Patients with Chronic Myeloid Leukemia Who Failed Previous Tyrosine Kinase Inhibitor Therapies

Senolytic Therapy Can Reverse Senescent Bone Marrow Stroma of Therapy-Related Myeloid Neoplasm

Clinical Outcomes of Chronic Myeloid Leukaemia (CML) Patients on Asciminib through the Managed Access Program (MAP) in Australia

ASC4FIRST: A Phase III Study of Asciminib vs Investigator-Selected Tyrosine Kinase Inhibitor in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Molecular Response of ≤10% BCR::ABL1 IS Is Predictive of Positive Outcomes in Treatment-Resistant Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Ponatinib from the Phase 2 Optic Trial

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only